On the surface, it’s an unsurprising move. AATD may affect 100,000 Americans. And it’s generally driven by a single misspelled letter, one that can be corrected with Prime’s technology.

Recently, BEAM reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. Unfortunately, they concurrently announced a $500 million equity offering ...

-- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP ...

The Cambridge-based base editing company, Beam Therapeutics, has announced initial safety and efficacy data from its Phase I/II trial of BEAM-302, establishing clinical proof-of-concept as a ...

(RTTNews) - Beam Therapeutics Inc. (BEAM) Monday reported positive initial data from its Phase 1/2 study of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an ...

Prime Medicine’s approach utilizes a proprietary lipid nanoparticle (LNP) delivery system to precisely target and correct the E342K mutation in the SERPINA1 gene, which is responsible for AATD.

Beam Therapeutics (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin ...

CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...